137999-87-2

Upstream product

• 60341-39-1 (E)-4-phenylbut-2-enoic acid 
• 507-09-5 tiolacetic acid 

Downstream Products

• 137999-88-3 2-(1-Carboxymethyl-2-phenyl-ethylsulfanylmethyl)-hexanoic acid methyl ester 
• 137999-90-7 (S)-2-((R)-1-Benzyl-3-morpholin-4-yl-3-oxo-propylsulfanylmethyl)-hexanoic acid 
• 137999-91-8 (2S,4S,5S)-6-Cyclohexyl-4-hydroxy-2-isopropyl-5-[(R)-2-((S)-4-morpholin-4-yl-4-oxo-1-phenyl-butane-2-sulfonylmethyl)-hexanoylamino]-hexanoic acid butylamide 
• 137999-91-8 (2S,4S,5S)-6-Cyclohexyl-4-hydroxy-2-isopropyl-5-[(S)-2-((R)-4-morpholin-4-yl-4-oxo-1-phenyl-butane-2-sulfonylmethyl)-hexanoylamino]-hexanoic acid butylamide 
• 137999-89-4 (S)-2-((R)-1-Benzyl-3-morpholin-4-yl-3-oxo-propylsulfanylmethyl)-hexanoic acid methyl ester 
• 260046-78-4 3-Acetylsulfanyl-4-phenyl-butyric Acid Benzyl Ester 

Relevant academic research and scientific papers

Sulfones as peptide bond isosteres

As part of an effort to design human renin inhibitors with improved bioavailability, the amino-terminal Phe-His element present in many classes of renin inhibitors was replaced by a sulfone containing isostere.

Hydroxamic acid derivatives as proteinase inhibitors

Compounds of formula (I) are matrix metalloprotemase inhibitors wherein X represents a carboxylic acid group —COOH, or a hydroxamic acid group —CONHOH;R2represents a radical of formula (II): R3—(ALK)m—(Q)p—(ALK)n., and W represents a cyclic amino radical of formula (IIIA) or (IIIB):